Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies by Yael Bar, Geoffrey Fell, Aylin Dedeoglu, Natalie Moffett, Neelima Vidula, Laura Spring, Seth A. Wander, Aditya Bardia, Naomi Ko, Beverly Moy, Leif W. Ellisen, Steven J. Isakoff

Get full text

Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in γ‐secretase inhibitor drug responses by Diana J. Azzam, Dekuang Zhao, Jun Sun, Andy J. Minn, Prathibha Ranganathan, Katherine Drews‐Elger, Xiaoqing Han, Manuel Picon‐Ruiz, Candace A. Gilbert, Seth A. Wander, Anthony J. Capobianco, Dorraya El‐Ashry, Joyce M. Slingerland

Get full text

Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2– breast cancer (LEADER) by Laura M. Spring, Lauren Scarpetti, Arielle J. Medford, Andrzej Niemierko, Amy Comander, Therese Mulvey, Lowell Schnipper, Steven J. Isakoff, Beverly Moy, Seth A. Wander, Jennifer Shin, Zanta Ephrem, Anneke R. Laposta, Elyssa Denault, Elizabeth Abraham, Gayle Calistro, Ekaterina Kalashnikova, Angel Rodriguez, Minetta C. Liu, Alexey Aleshin, Jeffrey Peppercorn, Leif W. Ellisen, Aditya Bardia

Get full text

A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancerResearch in context by Maxwell R. Lloyd, Rosario Chica-Parrado, Caroline M. Weipert, Todd C. Knepper, Emily L. Podany, Fabiana Napolitano, Dan Ye, Chang-Ching Lin, Yasuaki Uemoto, Jiemin Liao, Claire Wegrzyn, Christine M. Walko, Lianne Y. Ryan, Jennifer C. Keenan, Arielle J. Medford, Shiyuan A. Liu, Gerburg M. Wulf, Katherine K. Clifton, Cynthia X. Ma, Hyo S. Han, Nicole Zhang, Leif W. Ellisen, Aditya Bardia, Carlos L. Arteaga, Ariella B. Hanker, Seth A. Wander

Get full text